CD80 and cancer: Together, our data suggests that cancer vaccines may be boosted by both indirectly engaging T cells via influx of DCs and also by directly engaging T cells through co-stimulation and warrants the further investigation of CD80-Fc and Flt3L-Fc as potential “off the shelf” adjuvants to enhance tumor targeting immune responses.